# Sanofi to build $925M vaccine manufacturing facility in Toronto, Canada

Sanofi announced an investment of approximately CAD 925 million to build a new vaccine manufacturing facility at its existing site in Toronto, Canada. The facility will produce FLUZONE High-Dose Quadrivalent influenza vaccine and strengthen pandemic preparedness.

- Type: New facility
- Announced: 2021-03-31
- Where: Toronto, Ontario, Canada, Canada
- Value: $740.0M (925.0M CAD)
- Starts operating: 2026
- Status: announced
- Products: FLUZONE High-Dose Quadrivalent influenza vaccine

## Companies

- [Sanofi](https://endata.com/companies/10465.md)

## Sources

- [sanofi.com](https://www.sanofi.com/en/media-room/press-releases/2021/2021-03-31-14-05-00-2202566), 2021-03-31: "Sanofi today announced an investment of more than €600 million in a new vaccine manufacturing facility at its existing site in Toronto, Canada."
- [sanoficanada.mediaroom.com](https://sanoficanada.mediaroom.com/2021-03-31-Sanofi-to-build-new-manufacturing-facility-in-Toronto-to-strengthen-domestic-pandemic-preparedness-and-increase-global-supply-of-high-dose-influenza-vaccine), 2021-03-31: "Sanofi announced an investment of approximately $925 million (CAD) in a new vaccine manufacturing facility at its existing site in Toronto, Canada."
- [bioprocessintl.com](https://www.bioprocessintl.com/facilities-capacity/sanofi-to-build-700m-canadian-flu-vaccine-plant), 2021-04-01: "Fluzone High-Dose provides a long-term competitive advantage and this new investment will ensure more seniors around the world are better protected against influenza and its complications."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.